Related Experiment Video
Updated: Aug 2, 2025

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Emergence of Erythromycin-Resistant Invasive Group A Streptococcus, West Virginia, USA, 2020-2021
Abstract:
Clindamycin and β-lactam antibiotics have been mainstays for treating invasive group A Streptococcus (iGAS) infection, yet such regimens might be limited for strains displaying MLSB phenotypes. We investigated 76 iGAS isolates from 66 patients in West Virginia, USA, during 2020-2021. We performed emm typing using Centers for Disease Control and Prevention guidelines and assessed resistance both genotypically and phenotypically. Median patient age was 42 (range 23-86) years. We found 76% of isolates were simultaneously resistant to erythromycin and clindamycin, including all emm92 and emm11 isolates. Macrolide resistance was conferred by the plasmid-borne ermT gene in all emm92 isolates and by chromosomally encoded ermA, ermB, and a single mefA in other emm types. Macrolide-resistant iGAS isolates were typically resistant to tetracycline and aminoglycosides. Vulnerability to infection was associated with socioeconomic status. Our results show a predominance of macrolide-resistant isolates and a shift in emm type distribution compared with historical reports.
Insights
Macrolide resistance is a growing concern in invasive group A Streptococcus (iGAS) infections, impacting treatment options. This study highlights a high prevalence of resistant strains in West Virginia, USA.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Invasive group A Streptococcus (iGAS) infections are typically treated with clindamycin and beta-lactam antibiotics.
- Treatment efficacy may be compromised by macrolide, lincosamide, and streptogramin B (MLSB) resistance phenotypes in iGAS strains.
Purpose of the Study:
- To investigate the prevalence and characteristics of MLSB-resistant iGAS isolates in West Virginia.
- To identify the genetic mechanisms conferring macrolide resistance and assess associated resistance patterns.
Main Methods:
- emm typing of 76 iGAS isolates from 66 patients (2020-2021) following CDC guidelines.
- Genotypic and phenotypic assessment of antibiotic resistance, including macrolide resistance genes (ermT, ermA, ermB, mefA).
Main Results:
- 76% of iGAS isolates exhibited simultaneous resistance to erythromycin and clindamycin.
- emm92 and emm11 isolates were universally resistant to erythromycin and clindamycin.
- Macrolide resistance was linked to ermT, ermA, ermB, and mefA genes.
- Macrolide-resistant iGAS strains frequently showed co-resistance to tetracycline and aminoglycosides.
- Socioeconomic status was associated with iGAS infection vulnerability.
Conclusions:
- A significant predominance of macrolide-resistant iGAS isolates was observed.
- A shift in emm type distribution compared to historical data suggests evolving iGAS epidemiology.
- The findings underscore the need for ongoing surveillance of antibiotic resistance in iGAS.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Effectiveness
Antibiotic Selection
Endocarditis I: Introduction
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Endocarditis III: Medical Management

